Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805)
🥰Excellent
Catalog No. TMAY-01691
Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) is a Rabbit antibody targeting Phospho-VEGF Receptor 2 (Tyr1175). Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) can be used in WB.
Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805)
Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805)
🥰Excellent
Catalog No. TMAY-01691
Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) is a Rabbit antibody targeting Phospho-VEGF Receptor 2 (Tyr1175). Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) can be used in WB.
Product information is being updated, if you want to purchase, please click the bulk custom button.
Bulk & Custom
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) is a Rabbit antibody targeting Phospho-VEGF Receptor 2 (Tyr1175). Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) can be used in WB. |
| Ig Type | Monoclonal Rabbit IgG |
| Clone | 7E805 |
| Reactivity | Human; Predicted to React with:Species predicted to react based on 100% sequence homology: Cynomolgus, Pig |
| Verified Activity | 1. Western blot analysis of extracts from serum-starved HUVEC, untreated(line A) or treated with VEGF (50ng/mL, 2min; +)(line B), using Phospho-VEGF Receptor 2 (Tyr1175) rabbit monoclonal Antibody at 1:10000 dilution (upper) or Anti-Actin Antibody, Chimeric Rabbit Monoclonal at 1:50000 dilution (lower). 2. Western blot analysis of extracts from serum-starved HUVEC, untreated (line A); treated with VEGF (50ng/mL, 2min; +) (line B); treated with VEGF and λ-phosphatase (line C) using Phospho-VEGF Receptor 2 (Tyr1175) rabbit monoclonal Antibody at 1:10000 dilution. (Validation Experiment) 3. Western blot analysis of extracts from serum-starved HUVEC, untreated (line A); treated with VEGF (50ng/mL, 2min), without peptide (line B) or antigen-specific phosphopeptide (line C) or antigen-specific peptide (line D) using Phospho-VEGF Receptor 2 (Tyr1175) rabbit monoclonal Antibody at 1:10000 dilution. (Validation Experiment) |
| Application | WB |
| Recommended Dose | WB: 1:1000-1:10000 |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | This antibody was obtained from a rabbit immunized with a synthetic peptide corresponding to the residues around Tyr1175 of Human Phospho-VEGF Receptor 2. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 10 mM sodium HEPES, 150 mM NaCl, 100 μg/mL BSA, 50% glycerol, pH 7.5 |
| Research Background | VEGFR2 also called KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling are critical to endothelial cell survival, maintenance of the vasculature and alveolar structure, and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Conjucates | Unconjugated |
| Immunogen | A synthetic peptide corresponding to the residues around Tyr1175 of Human Phospho-VEGF Receptor 2 |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets, Hemangioblast Markers, Receptor Tyrosine Kinases (RTKs) |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |
Sci Citations
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) | purchase Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) | Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805) cost | order Anti-Phospho-VEGF Receptor 2 (Tyr1175) Antibody (7E805)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.